This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS

This study has been completed.
Information provided by (Responsible Party):
Michael Strong, Lawson Health Research Institute Identifier:
First received: September 5, 2006
Last updated: March 1, 2016
Last verified: March 2016
Muscular cramps are a common and uncomfortable symptom of amyotrophic lateral sclerosis (ALS). This clinical trial will compare the response of high dose vitamin E supplementation to placebo for treatment of muscular cramps in patients with ALS. We hypothesize that vitamin E will be more effective than placebo in treating cramps.

Condition Intervention Phase
Amyotrophic Lateral Sclerosis Dietary Supplement: Vitamin E Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis.

Resource links provided by NLM:

Further study details as provided by Michael Strong, Lawson Health Research Institute:

Primary Outcome Measures:
  • Reduction in number of muscle cramps experienced in a two week period. [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Reduction in the duration of cramps and reduction in the severity of cramps [ Time Frame: 4 weeks ]

Enrollment: 32
Study Start Date: December 2006
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Crossover group 1
Vitamin E first and placebo second
Dietary Supplement: Vitamin E
Vitamin E 800IU bid
Experimental: Crossover group 2
Placebo first then vitamin E
Dietary Supplement: Vitamin E
Vitamin E 800IU bid

Detailed Description:
This will be a single centre randomized placebo controlled crossover design trial. Participants will be randomized at study entry to protocol A (vitamin E first) or protocol B (placebo first). The first 2 weeks of the study will be a baseline assessment of the frequency, severity and duration of cramps. Patients will be blinded for the remainder of the duration of the study. For weeks 3-6 of the study, group A will receive vitamin E 800 IU bid and group B will receive placebo. For weeks 7-10 of the study, group A will receive placebo and group B will receive vitamin E. Participants will record cramp frequency and characteristics via a daily journal for the duration of the study, however the data analysis will focus on cramp frequency only during weeks 5-6 and 9-10. Weeks 3-4 and 7-8 will be used as time periods to allow the new drug to come to steady state and allow for washout of the previous drug. Data analysis will focus on the difference in cramp frequency in individual patients in each treatment period.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults (> age 18 years)
  • Probable or definite ALS by El Escorial Revised criteria
  • At least 2 painful muscle cramps in one or more of the limbs per week.
  • May have tried other medications for cramping in the past.
  • If participants are currently on treatment for cramps and are continuing to have at least 2 cramps per week, they can be included in the trial. In this situation, the individual's previous cramp medication can be continued during the trial.
  • Ideally, patients should not have any medication alterations during the duration of the trial.
  • Willing to discontinue supplementary vitamin E and multivitamins containing > 400 IU of vitamin E during the trial.

Exclusion Criteria:

  • Patients who are unable to safely consume the trial capsules. Individuals with significant dysphagia can be included into the study if they have a functioning PEG tube or GJ tube, through which the medication can be given.
  • Patients who are unable to fill out the daily diary, either personally or via a proxy.
  • Patients who have had medication changes within the last 4 weeks prior to the onset of the trial will be excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00372879

Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
Sponsors and Collaborators
Lawson Health Research Institute
Principal Investigator: Michael J Strong, MD, FRCPC Clinical Neurological Sciences, London Health Sciences Centre
Study Director: Christen L Shoesmith, MD, FRCPC Clinical Neurological Sciences, London Health Sciences Centre
  More Information

Responsible Party: Michael Strong, Professor Department of Clinical Neurological Sciences, Lawson Health Research Institute Identifier: NCT00372879     History of Changes
Other Study ID Numbers: R-06-451
Study First Received: September 5, 2006
Last Updated: March 1, 2016

Keywords provided by Michael Strong, Lawson Health Research Institute:
amyotrophic lateral sclerosis
vitamin E
muscle cramp

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Vitamin E
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents processed this record on September 21, 2017